Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.61 |
| ▸ | TP53 | P04637 | 3/20 | 0.61 |
| ▸ | CASP3 | P42574 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.52 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL118370 | 1.00 | MDM4 (0.61) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL30977677 | 1.00 | MDM4 (0.61) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL29366757 | 1.00 | MDM4 (0.61) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL29613402 | 1.00 | MDM4 (0.61) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL12537019 | 1.00 | MDM4 (0.61) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL29907974 | 1.00 | MDM4 (0.61) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL29352409 | 1.00 | MDM4 (0.61) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL29519824 | 0.95 | MDM4 (0.57) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL6742006 | 0.92 | MDM4 (0.55) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL29451083 | 0.91 | CASP3 (0.59) | MDM4TP53CASP3KMT2AMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166693-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPY 1 | Design Therapeutics, Inc. | 2024-05-23 | — | — | US | disclosed |
| EP-4259133-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPHY 1 | Design Therapeutics, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| WO-2022126000-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPHY 1 | Design Therapeutics, Inc. (US) | 2022-06-16 | — | — | WO | disclosed |
| US-20170119896-A1 | TERMINALLY MODIFIED POLYMERS AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2017-05-04 | — | — | US | disclosed |
| US-9257576-B2 | Amino acid generator and polysiloxane composition containing the same | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-02-09 | — | — | US | disclosed |
| US-20160021882-A1 | APPLICATION OF BIOFILM FORMATION INHIBITING COMPOUNDS ENHANCES CONTROL OF CITRUS CANKER | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20160021882-A1 | APPLICATION OF BIOFILM FORMATION INHIBITING COMPOUNDS ENHANCES CONTROL OF CITRUS CANKER | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2016-01-28 | — | — | US | disclosed |
| WO-2014008375-A1 | TERMINALLY MODIFIED POLYMERS AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. (US) | 2014-01-09 | — | — | WO | disclosed |
| US-20130313669-A1 | AMINO ACID GENERATOR AND POLYSILOXANE COMPOSITION CONTAINING THE SAME | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-11-28 | — | — | US | disclosed |
| CN-102037092-A | Amino acid generator and polysiloxane composition containing the same | NISSAN CHEMICAL IND LTD | 2011-04-27 | — | — | CN | disclosed |
| US-20110073977-A1 | AMINO ACID GENERATOR AND POLYSILOXANE COMPOSITION CONTAINING THE SAME | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166693-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPY 1 | MTPN, DMPK, MBNL1 | MDM4 1384/4885TP53 3195/4885CASP3 4522/4885 |
| US-20110073977-A1 | AMINO ACID GENERATOR AND POLYSILOXANE COMPOSITION CONTAINING THE SAME | DAO, BCAT1, BCAT2 | MDM4 1211/4885TP53 1965/4885CASP3 3774/4885 |
| US-20170119896-A1 | TERMINALLY MODIFIED POLYMERS AND CONJUGATES THEREOF | MALT1, ALG1, PRMT3 | MDM4 3621/4885TP53 1721/4885CASP3 993/4885 |
| US-20160021882-A1 | APPLICATION OF BIOFILM FORMATION INHIBITING COMPOUNDS ENHANCES CONTROL OF CITRUS CANKER | XDH, MYB, DDC | MDM4 2572/4885TP53 4486/4885CASP3 801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.